Cargando…
Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences
Translation of modulation of drug target activity to therapeutic effect is a critical aspect for all drug discovery programs. In this work we describe the profiling of a non-receptor tyrosine-protein kinase (TYK2) inhibitor which shows a functionally relevant potency shift between human and preclini...
Autores principales: | Gerstenberger, Brian S., Banker, Mary Ellen, Clark, James D., Dowty, Martin E., Fensome, Andrew, Gifford, Roger, Griffor, Matthew C., Hegen, Martin, Hollingshead, Brett D., Knafels, John D., Lin, Tsung H., Smith, James F., Vajdos, Felix F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265552/ https://www.ncbi.nlm.nih.gov/pubmed/32488071 http://dx.doi.org/10.1038/s41598-020-65762-y |
Ejemplares similares
-
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study
por: Singh, Ravi Shankar P., et al.
Publicado: (2020) -
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
por: Dowty, Martin E., et al.
Publicado: (2019) -
TYK2 in Tumor Immunosurveillance
por: Karjalainen, Anzhelika, et al.
Publicado: (2020) -
In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity
por: Prchal-Murphy, Michaela, et al.
Publicado: (2015) -
Association of germline TYK2 variation with lung cancer and non‐Hodgkin lymphoma risk
por: Yarmolinsky, James, et al.
Publicado: (2022)